 | | Vol. 14.40 – 10 October, 2023 |
| |
|
|
| Scientists showed that a calcium gradient exists in bone marrow microenvironments where HSCs reside and that extracellular calcium (eCa2+) and response to eCa2+ differed between leukemias.
[Nature Communications] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators utilized single-cell RNA sequencing to analyze pediatric AML bone marrow samples from diagnosis, end of induction, and relapse timepoints.
[Nature Communications] |
|
|
|
| Researchers showed that the cyclic guanosine monophosphate-adenosine monophosphate synthase-stimulator of interferon genes (STING) pathway was activated to mediate the effect of Ten-eleven translocation-2 (TET2) deficiency in dysregulated hematopoiesis in mouse models.
[Leukemia] |
|
|
|
| To test the functional impact of TWIST1 overexpression, scientists treated OCI-AML3s with TWIST1-siRNA or metformin, a drug known to inhibit tumor progression in cancer models.
[Leukemia] |
|
|
|
| Investigators demonstrated that pharmacological or genetic inhibition of signal transducer and activator of transcription 3 (STAT3) resulted in p53 induction and that CRISPR-mediated TP53 knockout substantially reverses susceptibility to STAT3 inhibition.
[Haematologica] |
|
|
|
| Researchers provided evidence that melatonin being a ‘’sleep regulating pineal hormone’’ directly inhibited migration of HSPCs both in vitro migration assays and in vivo during pharmacological mobilization.
[Stem Cell Reviews And Reports] |
|
|
|
| Human CD34+ hematopoietic stem and progenitor cells were exposed to 6 MV X-rays, mid- and distal spread-out Bragg peak protons at doses ranging from 0.5 to 2 Gy.
[Scientific Reports] |
| |
|
|
| Investigators analyzed 110 patients with relapsed/refractory B cell non-Hodgkin lymphoma or acute lymphoblastic leukemia, treated with axicabtagene-ciloleucel, tisagenlecleucel, or brexucabtagene autoleucel.
[Hemasphere] |
|
|
|
| Scientists revealed a novel role for O-linked N-acetylglucosamine transferase (OGT) during embryogenesis, which ensured the survival of fetal liver hematopoietic cells partly by regulating Bcl-xL and oxidative phosphorylation.
[Stem Cells] |
|
|
|
|
| The authors provide a summary of what is known in the field, challenges in the management of Down syndrome patients with leukemia, and key questions in the field.
[Haematologica] |
|
|
|
| | Starton Therapeutics Inc. announced the dosing of the first patient in the subcutaneous administration of low-dose lenalidomide (STAR-LLD) Phase Ib clinical trial, which will assess the safety, efficacy, and pharmacokinetics of continuous STAR-LLD for the treatment of multiple myeloma.
[Starton Therapeutics, Inc.] |
|
|
|
|
| October 29 – November 3, 2023
Hinxton, England, United Kingdom |
|
|
|
|
|
| | University of San Francisco – San Francisco, California, United States |
|
|
|
| | University of Nebraska Medical Center – Omaha, Nebraska, United States |
|
|
|
| | University of North Carolina at Chapel Hill – Chapel Hill, North Carolina, United States |
|
|
|
| | Houston Methodist Research Institute – Houston, Texas, United States |
|
|
|
| | Versiti Blood Research Institute – Wisconsin Rapids, Wisconsin, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
